Education
About Us
Working with TipRanks
Follow Us
Harrow Health Inc (HROW)
NASDAQ:HROW
HROW Stock Chart & Stats
$53.59
-$0.36(-1.00%)
At close: 4:00 PM EST
$53.59
-$0.36(-1.00%)
Day’s Range― - ―
52-Week Range$20.85 - $54.85
Previous CloseN/A
Volume51.77K
Average Volume (3M)493.61K
Market Cap
$1.98B
Enterprise Value$2.16B
Total Cash (Recent Filing)$72.93M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.28
Next Earnings
May 07, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding37,037,453
10 Day Avg. Volume484,206
30 Day Avg. Volume493,607
Financial Highlights & Ratios
PEG Ratio4.91
Price to Book (P/B)34.35
Price to Sales (P/S)6.61
P/FCF Ratio0.00
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue7.94
Enterprise Value/Gross Profit10.58
Enterprise Value/Ebitda59.24
Forecast
1Y Price Target
$74.00Price Target Upside38.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.36
Revenue Forecast (FY)$391.40M
Bulls Say, Bears Say
Bulls Say
Commercial ExpansionCompany is expanding and broadening its U.S. salesforce and geographic coverage, which could improve market penetration for core therapies and accelerate branded revenue growth.
Portfolio EnhancementPlanned launches of a new topical corticosteroid, additional eye treatments, and a sublingual sedation formulation could expand treatment options and unlock new revenue streams in office-based and surgical settings.
Product DemandAnalyst's recommendation reflects strong demand for Iheezo, evidenced by rising sales and growing customer adoption that could support revenue momentum.
Bears Say
Biosimilar CompetitionMultiple competing aflibercept biosimilars, together with historical challenges for Lucentis biosimilars, create headwinds that could constrain market share and pricing for new entrants.
Reimbursement RiskLoss of pass-through reimbursement for certain products could reduce volumes that depend on ambulatory surgical centers and weaken sales where that payment status supported utilization.
Rising Operating CostsHigher operating expenses from increased selling and administrative costs plus acquisition-related research and development charges have reduced reported net income and could pressure profitability.
Harrow Health News
HROW FAQ
What was Harrow Health Inc’s price range in the past 12 months?
Harrow Health Inc lowest stock price was $20.85 and its highest was $54.85 in the past 12 months.
What is Harrow Health Inc’s market cap?
Harrow Health Inc’s market cap is $1.98B.
When is Harrow Health Inc’s upcoming earnings report date?
Harrow Health Inc’s upcoming earnings report date is May 07, 2026 which is in 64 days.
How were Harrow Health Inc’s earnings last quarter?
Harrow Health Inc released its earnings results on Mar 02, 2026. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.368 by -$0.198.
Is Harrow Health Inc overvalued?
According to Wall Street analysts Harrow Health Inc’s price is currently Undervalued.
Does Harrow Health Inc pay dividends?
Harrow Health Inc does not currently pay dividends.
What is Harrow Health Inc’s EPS estimate?
Harrow Health Inc’s EPS estimate is -0.2.
How many shares outstanding does Harrow Health Inc have?
Harrow Health Inc has 37,037,453 shares outstanding.
What happened to Harrow Health Inc’s price movement after its last earnings report?
Harrow Health Inc reported an EPS of $0.17 in its last earnings report, missing expectations of $0.368. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Harrow Health Inc?
Currently, no hedge funds are holding shares in HROW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harrow Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.00 (38.09% Upside)
$74.00 (38.09% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 57.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Bullish
Bullish news 69%
Bearish news 31%
Bearish news 31%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.84%
12-Months-Change
Fundamentals
Return on Equity
-9.54%
Trailing 12-Months
Asset Growth
3.39%
Trailing 12-Months
Company Description
Harrow Health Inc
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
HROW Company Deck
HROW Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive outlook: strong 2025 financial performance with double‑digit revenue growth, significant adjusted EBITDA expansion, healthy cash generation, multiple product-specific accelerations (BYOOVIZ, IHEEZO, TRIESENCE, VEVYE), concrete 2026 guidance with clear second‑half weighting, and promising pipeline milestones (G-MELT NDA target, IHEEZO data flow). Near‑term headwinds — Q1 seasonality/channel drawdown, ASC pass‑through loss for IHEEZO, compounding inventory issues, and planned SG&A/R&D investments — are acknowledged and largely presented as manageable or temporary in nature. Given the weight and scale of the positive operating and financial indicators relative to the near-term, addressable challenges, the overall tone is constructive and growth‑oriented.View all HROW earnings summariesHROW Stock 12 Month Forecast
Average Price Target
$74.00
▲(38.09% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Ownership Overview
26.75% Insiders
9.99% Mutual Funds
6.10% Other Institutional Investors
46.25% Public Companies and Individual Investors